高级检索
当前位置: 首页 > 详情页

Comprehensive Plasma N-Glycoproteome Profiling Based on EThcD-sceHCD-MS/MS

文献详情

资源类型:
Pubmed体系:
机构: [1]Institute of Thoracic Oncology,West China Hospital, Sichuan University, Chengdu, China, [2]Institutes for Systems Genetics, West China Hospital, Sichuan University, Chengdu, China, [3]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China, [4]Mass Spectrometry Engineering Technology Research Center, Center for Advanced Measurement Science, National Institute of Metrology, Beijing, China
出处:
ISSN:

关键词: mass spectrometry plasma N-glycoproteomics combinatorial peptide ligand library EThcD-sceHCD

摘要:
Glycoproteins are involved in a variety of biological processes. More than one-third of the plasma protein biomarkers of tumors approved by the FDA are glycoproteins, and could improve the diagnostic specificity and/or sensitivity. Therefore, it is of great significance to perform the systematic characterization of plasma N-glycoproteome. In previous studies, we developed an integrated method based on the combinatorial peptide ligand library (CPLL) and stepped collision energy/higher energy collisional dissociation (sceHCD) for comprehensive plasma N-glycoproteome profiling. Recently, we presented a new fragmentation method, EThcD-sceHCD, which outperformed sceHCD in the accuracy of identification. Herein, we integrated the combinatorial peptide ligand library (CPLL) into EThcD-sceHCD and compared the performance of different mass spectrometry dissociation methods (EThcD-sceHCD, EThcD, and sceHCD) in the intact N-glycopeptide analysis of prostate cancer plasma. The results illustrated that EThcD-sceHCD was better than EThcD and sceHCD in the number of identified intact N-glycopeptides (two-folds). A combination of sceHCD and EThcD-sceHCD methods can cover almost all glycoproteins (96.4%) and intact N-glycopeptides (93.6%), indicating good complementarity between the two. Our study has great potential for medium- and low-abundance plasma glycoprotein biomarker discovery.Copyright © 2022 Mao, Su, Lin, Yang, Zhao, Zhang and Dai.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 3 区 化学
小类 | 3 区 化学:综合
最新[2023]版:
大类 | 3 区 化学
小类 | 3 区 化学:综合
第一作者:
第一作者机构: [1]Institute of Thoracic Oncology,West China Hospital, Sichuan University, Chengdu, China,
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43370 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号